


Stanford



Lauren Maeda

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2325

MC 6505

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 498-5030

Bio

CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Lymphoma
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

PROFESSIONAL EDUCATION

- Medical Education: Stanford University School of Medicine (2006) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2011) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2012)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2009)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma, Recruiting
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, Not Recruiting

-
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
 - A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Not Recruiting
 - A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects # 65 Years With Newly-Diagnosed Acute Myeloid Leukemia, Not Recruiting
 - A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
 - A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO), Not Recruiting
 - A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia., Not Recruiting
 - A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma, Not Recruiting
 - A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma, Not Recruiting
 - A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma, Not Recruiting
 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma, Not Recruiting
 - A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome, Not Recruiting
 - A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6, Not Recruiting
 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies, Not Recruiting
 - A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001, Not Recruiting
 - An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
 - An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Not Recruiting
 - Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma, Not Recruiting
 - Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma, Not Recruiting
 - Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting
 - Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma, Not Recruiting
 - Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma, Not Recruiting
 - Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting
 - Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
 - Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies, Not Recruiting
 - ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas, Not Recruiting
 - Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
 - Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
 - Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting
 - Efficacy of Axicabtagene Ciloleucef Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
 - Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission, Not Recruiting
 - Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia, Not Recruiting
 - Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT), Not Recruiting

- Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy., Not Recruiting
- Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer, Not Recruiting
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma, Not Recruiting
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia, Not Recruiting
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia, Not Recruiting
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Not Recruiting
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma, Not Recruiting
- Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087), Not Recruiting
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting
- Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies, Not Recruiting

Publications

PUBLICATIONS

- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755-+
- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; JCO1801907
- **Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.** *Cureus*
Albahr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., Ajlan, A.
2018; 10 (11): e3660
- **Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma**
Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., Sworder, B., Soo, J., Glover, C., Roschewski, M., Wilson, W. H., Duhrsen, U., Huettmann, et al
AMER SOC HEMATOLOGY.2018
- **Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review** *CUREUS*
Albahr, A., Alhothali, W., Samghabadi, P., Maeda, L., Nagpal, S., Ajlan, A.
2018; 10 (11)
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*

Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al

2018; 36 (28): 2845-+

● **Circulating tumor DNA (ctDNA) in B-cell lymphoma**

Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al

WILEY.2018: 16-17

● **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al

2018: JCO2018785246

● **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*

Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultides, et al

AMER SOC HEMATOLOGY.2016

● **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**

Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultides, et al

AMER SOC HEMATOLOGY.2016

● **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**

Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al

AMER SOC HEMATOLOGY.2016

● **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*

Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al

2016; 8 (364)

● **Noninvasive molecular subtyping and risk stratification of DLBCL.**

Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al

AMER SOC CLINICAL ONCOLOGY.2016

● **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**

Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al

AMER SOC HEMATOLOGY.2015

● **Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*

Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., Staudt, L. M., Jaffe, E. S., Wilson, et al

2013; 368 (15): 1408-1416

● **A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma** *LEUKEMIA & LYMPHOMA*

Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., Lossos, I. S.

2012; 53 (7): 1299-1305

● **Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*

Nair, V. S., Maeda, L. S., Ioannidis, J. P.

2012; 104 (7): 528-540

● **STAGE I-III A NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*

Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.

2011; 81 (5): 1374-1379

- **Current concepts and controversies in the management of early stage Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*
Maeda, L. S., Lee, M., Advani, R. H.
2011; 52 (6): 962-971
- **The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma** *CURRENT OPINION IN ONCOLOGY*
Maeda, L. S., Advani, R. H.
2009; 21 (5): 397-400
- **Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease** *9th International Conference on Malignant Lymphoma*
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2007: 3902-7
- **Transcription arrest at an abasic site in the transcribed strand of template DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*
Tornaletti, S., Maeda, L. S., Hanawalt, P. C.
2006; 19 (9): 1215-1220
- **Transcriptional inhibition by an oxidized abasic site in DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*
Wang, Y. L., Sheppard, T. L., Tornaletti, S., Maeda, L. S., Hanawalt, P. C.
2006; 19 (2): 234-241
- **Effect of 8-oxoguanine on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *DNA REPAIR*
Silvia, T. A., Maeda, L. S., Kolodner, R. D., Hanawalt, P. C.
2004; 3 (5): 483-494
- **Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Tornaletti, S., Maeda, L. S., Lloyd, D. R., Reines, D., Hanawalt, P. C.
2001; 276 (48): 45367-45371